ClinicalTrials.gg
CompletedNCT03641261e-ETPichtyoseUpdated Apr 12, 2024

Therapeutic Education Using an Internet Application in Hereditary Ichthyosis

An interventional study of Therapeutic patient education program in Ichthyosis, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 15 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
15 Years to 60 Years
Sex
All
01

Study summary

The main purpose is to evaluate the feasibility (global use) of a therapeutic patient education program using a specific web application in patients with hereditary ichthyosis.

02

Conditions studied

  • Ichthyosis

Browse trials for

Keywords

  • Hereditary ichthyosis
03

In context

Ichthyosis

33 studies on the registry are indexed under Ichthyosis; 11 are open to participants now.

This study's enrollment of 42 is above the median of 26 across 23 interventional studies indexed under Ichthyosis.

Browse Ichthyosis studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with hereditary ichthyosis, according to the classification established during the 2009 consensus conference
  • Who has given his form
  • Who is affiliated to a social security system

Exclusion criteria

Exclusion Criteria:

  • Patient who has already participated in a therapeutic patient education program for the hereditary ichthyosis
  • Unable to connect or use a computer tool
  • Impossibility to be present at the only face-to-face session
  • Patient who is not available for the collective educational session
  • Patient with little or no motivation to follow a therapeutic patient education program (motivation evaluated by the educational team by phone call before inclusion)
  • Patient not mastering the French language
  • Person under legal protection (guardianship, curators or safeguard of justice)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Therapeutic Patient Education program

    All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose

    Other: Therapeutic patient education program

Interventions

  • OtherTherapeutic patient education program

    WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team

    Also known as: WebIchtyose

06

What researchers measure

Primary outcomes

  1. Global use

    percentage of patients who have used the "WebIchtyose" application for at least 8 hours during 6 months

    Time frame: 6 months

Secondary outcomes

  1. Fractional use in each domain (educational sessions)

    "WebIchtyose" application use time by the patient for group and individual educational sessions

    Time frame: 6 months

  2. Fractional use in each domain (continuous educational follow-up)

    "WebIchtyose" application use time by the patient for the continuous educational follow-up

    Time frame: 6 months

  3. Fractional use in each domain (consultation)

    "WebIchtyose" application use time by the patient for the consultation of the "Frequently Asked Questions" area and of patient information documents made available on the application

    Time frame: 6 months

  4. Fractional use in each domain (questionnaires)

    "WebIchtyose" application use time by the patient for the filling of the questionnaires

    Time frame: 6 months

  5. Fractional use in each domain

    "WebIchtyose" application use time by the patient for group and individual educational sessions, the continuous educational follow-up, the consultation of the "Frequently Asked Questions" area and of patient information documents made available on the application

    Time frame: 6 months

  6. Difficulty of individual application registration

    Difficulty of registration questionnaire completed for each patient jointly by the patient and the educational team at the end of the face-to-face inclusion visit

    Time frame: Baseline

  7. Difficulties of use in everyday life by the patient

    Questionnaire completed for each patient jointly by the patient at the end of the program

    Time frame: 6 months

  8. Number of exchanges

    Number of exchanges necessary between the educational team and the patient to set a date for the conduct of the individual educational sessions

    Time frame: 3 months and 5 months

  9. Response time

    Response time of the educational team following a request from the patient as part of the educational follow-up

    Time frame: 6 months

  10. Number of relaunches

    How many times the nurse relaunches the patient to obtain the assessment questionnaires

    Time frame: 2 months, 4 months and 6 months

  11. Number of non-received questionnaires

    Number of non-received questionnaires after relaunch

    Time frame: 2 months, 4 months and 6 months

  12. Number of lost to follow-up patients

    Number of lost to follow-up patients

    Time frame: 9 months

  13. Patient acceptability

    Acceptability questionnaire to be completed by the patient

    Time frame: 6 months

  14. Educational team acceptability

    Acceptability questionnaire to be completed by each member of the educational team

    Time frame: 6 months

  15. Attractiveness

    Application attractiveness questionnaire completed by the patient

    Time frame: 6 months

  16. Quality of life before and after treatment

    Quality of life questionnaire for hereditary ichthyosis (IQoL-32)

    Time frame: Inclusion, 6 months and 9 months

  17. Self-assessment of cutaneous severity

    Self-assessment of cutaneous severity according to an analogic visual scale for pain, pruritus, erythema, squama

    Time frame: Inclusion and 6 months

  18. Knowledge about disease and treatments

    Questionnaire of knowledge about disease and treatments

    Time frame: Inclusion and 6 months

  19. Self-care skills

    Questionnaire of self-care skills

    Time frame: Inclusion and 6 months

  20. Self-esteem

    Questionnaire about self-esteem: Rosenberg scale. For each item of the questionnaire, the modality answers are : 1 (totally disagree), 2 (quite disagree), 3 (quite agree) and 4 (totally disagree). The total score (/ 40) is calculated by adding the scores obtained for each item.

    Time frame: Inclusion and 6 months

  21. Coping scale

    Coping with health injuries and problem (Endler 1998). For each item of the questionnaire, the modality answers are: 1 (not at all), 2 (a little), 3 (moderately), 4 (often) and 5 (a lot).The total score (/ 160) is calculated by adding the scores obtained for each item.

    Time frame: Inclusion and 6 months

07

Study locations

1 site
  • CHU Toulouse, Hôpital Larrey
    Toulouse, 31059, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03641261
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Oct 29, 2018
Primary completion
Feb 21, 2023
Completion
Feb 21, 2023
Last update
Apr 12, 2024

Study contacts

Juliette Mazereeuw-Hautier, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion